Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06678841 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ELEVATE-HFpEF Clinical Study

Study acronym: ELEVATE-HFpEF
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 50 to 51
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 5 of 5 entries
  2. Trial sites expanded: 46 → 50 locationsv16
  3. Study sites: 44 to 46v15
  4. Study sites: 42 to 44v14
  5. Trial sites expanded: 34 → 42 locationsv13
  6. Trial sites expanded: 28 → 34 locationsv12
  7. Study sites: 20 to 28v11
  8. Study sites: 17 to 20v10
  9. Study sites: 13 to 17v9
  10. Study sites: 9 to 13v8
  11. Study sites: 5 to 9
    • Study description shortened, about 3 words
    v7
  12. Study sites: 3 to 5v6
  13. Study sites: 2 to 3
    • Start date changed from estimate of Aug 2025 to Jul 9, 2025
    v5
  14. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    v4
  15. Primary endpoints revised (2)v3 Show 4 more changesShow less
    • Interventions: Personalized elevated cardiac pacing (Device) to Personalized cardiac pacing (Device)
    • Eligibility criteria shortened, about 8 words
    • Secondary endpoints revised (5)
    • Study description expanded, about 35 words
  16. Primary completion date: Nov 2026 to Aug 2028
    • Start date: Apr 2025 to Aug 2025
    • Study completion date: Oct 2029 to Feb 2029
    v2
  17. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).
Trial Details
NCT Number NCT06678841
Lead Sponsor Medtronic Cardiac Rhythm and Heart Failure
Conditions
(from sponsor)		 Heart Failure With Preserved Ejection Fraction (HFpEF)
Related terms Cardiovascular Diseases, Heart Diseases, Heart Failure
Enrollment 700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov